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ABSTRACT
Introduction: Cost-containment strategies are
shifting the treatment of acute bacterial skin
and skin structure infections (ABSSSI) from
inpatient to outpatient settings. Current
standard of care (SoC) requires multiple-dose
regimens, which are associated with high
hospitalization rates and high costs.
Oritavancin, a new single-dose antibiotic for
ABSSSI, may be suitable for outpatient therapy.
This analysis evaluates the effectiveness, costs,
and resource utilization of oritavancin vs. SoC
in a real-world, outpatient setting.
Methods: A single-site, retrospective
chart review was conducted of 118 adult
patients diagnosed with ABSSSI and treated
with either single-dose oritavancin or
multi-dose SoC therapy between 6 August
2014 and 30 June 2015. Patients were assigned
to two matched cohorts: oritavancin and SoC.
Primary clinical effectiveness endpoints was the
success (cured or improved) at 5–30 days after
the course of antibiotic therapy has been
completed. Secondary economic endpoints
were total costs and healthcare resource
utilization.
Results: Oritavancin showed comparable
clinical effectiveness vs. multi-dose SoC in the
outpatient setting. A similar percentage of
patients in the oritavancin (90.2%) and SoC
cohorts (77.4%) achieved successful outcomes
(‘‘cure’’ or ‘‘improved’’), with the cure rate
higher for oritavancin (73.2%) vs. SoC (48.4%;
P = 0.0315). Oritavancin’s clinical effectiveness
was consistent across patient subgroups with
varying demographic, clinical, and ABSSSI
characteristics. Oritavancin was consistently
associated with lower costs (per-patient savings
$2319) and reduced resource utilization
measures, and it required just 1.0 day of
therapy vs. 7.2 days for SoC.
Conclusion: Oritavancin is well suited for the
outpatient treatment of ABSSSI. Compared with
SoC, oritavancin offers comparable
effectiveness, is more economical, and requires
fewer healthcare resources.
Enhanced content To view enhanced content for this
article go to http://www.medengine.com/Redeem/
D257F060381D5215.
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INTRODUCTION
Total US healthcare spending now exceeds $3
trillion annually, or approximately $9523 per
person, and 32% of that cost is spent on
hospital care [1]. Acute bacterial skin and skin
structure infections (ABSSSI) represent the tenth
leading cause for non-maternal/non-neonatal
hospital admissions, comprising a total of
569,259 admissions in 2013 and representing
$14 billion in healthcare spending for hospital
care alone [2]. Despite being a top-ten reason for
admission, the mortality rate for these
infections is only 0.08% [3].
The high utilization of the hospital inpatient
setting for a low acuity condition is due in part
to the increasing incidence of
community-acquired methicillin-resistant
Staphylococcus aureus (CA-MRSA), which
comprises up to 60% of all ABSSSI cases [4–6].
Treatment of MRSA frequently requires
intravenous (IV) antibiotics, and because of
the time it takes to identify the pathogen,
patients are often admitted and treated
empirically with IV MRSA-active antibiotics
when MRSA is suspected.
Infectious Disease Society of America (IDSA)
guidelines indicate that treatment for severe
ABSSSI should include antibiotic treatment with
IV antibiotics including vancomycin,
daptomycin, linezolid, telavancin, or
ceftaroline, all of which require multiple doses
over several days [7]. Further, vancomycin
requires regular serum monitoring for toxicity,
another reason for potential hospital admission.
A 2015 study funded by the US Centers for
Disease Control and Prevention found that
emergency room (ER) physicians cited the
need for multi-dose intravenous (IV)
antibiotics as a reason for admission for 85%
of ABSSSI admissions, with IV antibiotics the
sole reason for admission in 41.5% of cases [8].
Similarly, a 2015 study determined that 67% of
patients hospitalized for ABSSSI had no
life-threatening conditions and one or no
comorbidities, indicating that a substantial
portion of hospitalized ABSSSI patients have
no clinical rationale for admission [3].
The cost-saving potential of treating ABSSSI
patients in the outpatient instead of inpatient
setting may be substantial. Non-drug medical
costs for ABSSSI care has been estimated to
range from $9813 to $18,014 in the inpatient
setting compared with $4039 to $4924 for
outpatient management [5]. Clinical studies
indicate that outcomes may be equally good
in the outpatient setting [3, 8], although
delivery of successful outpatient care may be
difficult for both provider and patient when
multiple days of IV therapy are required.
Orbactiv (oritavancin for injection, The
Medicines Company, Parsippany, NJ), a novel
semisynthetic lipoglycopeptide antibiotic, is
approved to treat ABSSSI caused by
gram-positive pathogens, including MRSA.
Oritavancin is administered as a one-time,
single-dose infusion, making it a strong
candidate for outpatient treatment of ABSSSI.
The introduction of newer antibiotics like
oritavancin, with one-time dosing and fewer
intensive monitoring requirements, may be a
good solution to the current pressure to manage
healthcare costs through reduction of hospital
utilization while maintaining quality of care
[9–11]. However, little is known about the
outcomes and costs of ABSSSI treatment in a
real-world outpatient setting. The objective of
this analysis was to compare and evaluate
clinical outcomes, healthcare costs, and
resource utilization associated with single-dose
oritavancin vs. multi-dose standard of care
(SoC) antibiotics for the treatment of ABSSSI
in a real-world outpatient setting.
METHODS
Study Design
This single-center, retrospective, observational
study evaluated patients treated for ABSSSI
caused by suspected or confirmed
gram-positive pathogens with single-dose
oritavancin or SoC antibiotics in an outpatient
infusion center. Patient charts were abstracted
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retrospectively to determine study eligibility.
Demographic and infection characteristics,
microbiological laboratory results, clinical
outcomes, and resource utilization data were
extracted from patient records. Patients who
received at least one 1200 mg dose of
oritavancin between 6 August 2014 and 30
June 2015 were matched to patients who
received SoC antibiotics (defined by protocol
as any IV antibiotics indicated for ABSSSI and
routinely used in practice at this infusion
center). Both cohorts were evaluated during
the index treatment period, which started when
the patient received the first dose of study drug
at the infusion center and ended when the
patient completed the course of study drug, and
for 30 days after index treatment, to assess
outcomes, related resource use, and costs.
Setting
The study took place at Emerald Coast
Infectious Diseases Medical Group, PA, a
single-center, stand-alone, outpatient infusion
center located in Fort Walton Beach, Florida,
USA.
Patients
Patients who met the following criteria were
eligible for study enrollment: age C18 years
with a confirmed diagnosis of wound
infection, cellulitis/erysipelas, or major
cutaneous abscess suspected/proven to be due
to gram-positive pathogens, including MRSA,
between 6 August 2014 and 30 June 2015, who
received either single-dose oritavancin or SoC
antibiotics. It was required that all medical
chart data be available for abstraction into a
case report form. Patients were excluded from
the study if they were enrolled in other
ABSSSI-related clinical trial(s) between 6
August 2014 and 30 June 2015. Lesion size
measurements were not routinely collected in
patient charts and were therefore not used as
eligibility criteria. All patients met the criteria
for ABSSSI diagnosis according to the
investigating physician.
Patients with a confirmed ABSSSI diagnosis
who received oritavancin at the outpatient
infusion center were enrolled first and then
matched on a 1:1 basis with patients with a
confirmed ABSSSI diagnosis who received SoC
antibiotics. Three mandatory matching criteria
were applied: age (\65 or C65 years), history of
diabetes (type 1 or type 2, or none), and
infection type (cellulitis, wound, or abscess). If
an oritavancin-treated patient could be
matched to more than one SoC-treated patient
based on these mandatory criteria, four
additional matching criteria were then applied
from highest to lowest priority: body mass
index (BMI \30 or C30 kg/m2), insurance
status (Medicare, Medicaid, commercial, or
self-pay), gender (male or female), and fever
(\100.4 or C100.4 F).
Patient baseline and post-treatment vital
sign data were collected, including blood
pressure, temperature, and heart and
respiratory rate. When available, baseline
microbiology was assessed to determine
whether infections comprised gram-positive
organisms only or both gram-negative and
-positive organisms. Patients who presented
with Staphylococcus aureus organisms were
further delineated into methicillin-resistant
Staphylococcus aureus (MRSA) or
methicillin-susceptible Staphylococcus aureus
(MSSA).
Prior to study initiation, a pilot study was
conducted at the infusion center site to confirm
the availability of comprehensive medical
records data for both study cohorts and to
identify any data access issues that might arise.
Fifty-nine oritavancin patients were found
eligible for inclusion; a total of 200 SoC
patients were identified as the eligible
matching pool.
Primary Effectiveness Outcome
Clinical response was classified as ‘‘cured,’’
‘‘improved,’’ ‘‘failure,’’ or ‘‘non-evaluable’’ and
assessed at 5–30 days after the course of
antibiotic therapy had been completed in the
outpatient center. This approach followed
standard practice at this center, in which
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patients are scheduled for a follow-up visit
within 30 days of treatment whenever
possible. The clinical definitions were as
follows: (a) cured: resolved clinical signs and
symptoms alongside clinician documentation
of cure and/or no additional antibiotic therapy
prescribed; (b) improved: partial resolution of
clinical signs and symptoms, clinician
documentation of improvement and/or no
additional antibiotic therapy needed;
(c) failure: inadequate resolution or new or
worsening clinical signs and symptoms, such
that additional antibiotic therapy is necessary
for treatment of the infection;
(d) non-evaluable: inability to determine
response because the patient record did not
contain the necessary information.
Following this, the percentage of evaluable
patients classified as ‘‘success’’ (defined as cured
or improved) was calculated and compared
between the oritavancin and SoC cohorts.
Economic Outcomes
Total healthcare costs were defined as the costs
incurred at the infusion center from study drug
initiation (oritavancin or SoC antibiotic) to the
end of the study period. Total costs were further
broken down into: medication costs, drug
administration costs, IV supply costs, office/
outpatient visit costs, ABSSSI procedure costs,
hospital care costs, and other. The infusion
center billing charges were collected.
Medication costs were estimated based on
wholesale acquisition cost and drug dosage; all
non-medication services costs were estimated
based on billing charges and a unified
cost-to-charge ratio (CCR) of 1:2. The CCR of
1:2 was estimated based on ratios of Centers for
Medicare and Medicaid Services physician fee
payments in the Florida area vs. actual charges.
In addition, healthcare resource utilization
during the index treatment period and for
30 days before and after the index treatment
period was evaluated for both groups.
Healthcare resource utilization metrics
included: prior ER visits or hospitalization
(including for the same episode of skin
infection within 30 days of first dose of index
antibiotic); additional antibiotics needed
during the index and post-index periods;
number of days for infusion center visits;
additional clinical follow-up such as ER visits,
hospitalization or re-hospitalization for the
original episode of care (within 30 days of the
last dose of index antibiotic therapy at the
infusion center).
Statistical Analysis
All data were summarized by treatment group
(oritavancin, SoC) using descriptive statistics
and graphs. Due to the descriptive nature of the
study, no formal sample size calculations were
conducted. Descriptive statistics for continuous
variables included the mean, standard
deviations (SD), medians, and minimum and
maximum. Categorical variables were
summarized by frequencies and percentages.
Comparisons between the oritavancin and SoC
groups were conducted using chi-square or
Fisher exact tests (cell count\5) for categorical
and Wilcoxon rank-sum tests for continuous
variables. For the primary effectiveness
outcome, the success rate was defined as:
Success rate %ð Þ
¼ Number of patients with cure or improved
Number of patients with cure; improved; or failure
 100%:
The success rate difference between
oritavancin and SoC groups (=rate of SoC
group - rate of oritavancin) was calculated,
and the 95% two-sided confidence interval (CI)
of this observed difference was constructed.
P values were calculated based on the
chi-square test. Furthermore, the success rate
was analyzed by various clinically relevant
subgroups, such as age, gender, diabetes status,
infection type, and others. No alpha adjustment
was made for multiple comparisons. For the
economic outcome, total healthcare costs were
summarized as mean (SD) and median
(minimum, maximum) by oritavancin and
SoC groups and compared using Wilcoxon
rank-sum tests. Subgroup analyses were
conducted for both clinical and economic
outcomes. With the exception of a sensitivity
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analysis on the primary effectiveness outcome
(conducted the explore the impact of missing
data on results), missing data values or
unknown data were not imputed. Data
processing, summarization, and analyses were
performed using SAS version 9.2 (SAS Inc., Cary,
NC, USA).
Sensitivity Analysis
A sensitivity analysis was performed to evaluate
the robustness of the primary effectiveness
outcome of success rate. In the primary
analysis of clinical success, patients with
non-evaluable data were excluded entirely
because no information was available.
Sensitivity analyses were conducted by
creating two scenarios using the non-evaluable
data. First, non-evaluable responses were
categorized as ‘‘cured or improved’’ and
included in both the denominator and
numerator when calculating the success rate.
Second, non-evaluable responses were
re-categorized as ‘‘failure’’ and included in
denominator but not in the numerator. All
other effectiveness comparisons were
conducted in this fashion.
Compliance with Ethics Guidelines
All procedures followed were in accordance
with ethical standards. A waiver of
institutional review consent was granted by
the New England Internal Review Board
(NEIRB). This study was conducted
retrospectively, and all protected,
patient-identifiable information was not
shared with the Sponsor or anyone outside of
the study site. Data abstraction,
de-identification, and entry were performed
onsite at the infusion clinic by an
independent Clinical Research Organization,
Medical Data Analytics (MDA) of Parsippany,
NJ.
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1964, as revised in
2013. This article is based on previously
completed treatment of patients and does not
involve any new interventions performed on
human or animal subjects by any of the
authors. This was a retrospective study;
informed consent was waived.
RESULTS
Patient Characteristics
A total of 118 patients (59 oritavancin and 59
SoC) met all mandatory matching criteria and
were included in the study. As shown in Table 1,
patients were similar in terms of mean age (65.3
and 63.8 years in oritavancin and SoC,
respectively), primarily female (n = 30 and
n = 38), and predominantly white (n = 55 and
n = 53). SoC patients received the following IV
antibiotics: daptomycin (n = 34, 58%),
dalbavancin (n = 15, 25%), vancomycin (n = 3,
5%), or other antibiotics (n = 7, 12%). Dosing
schedule of drugs was based on prescribing
information: daptomycin once daily,
dalbavancin once weekly for 2 weeks; and
vancomycin twice daily. Choice of antibiotic
was based on physician discretion considering
the best option for each individual patient. All
treatment decisions were made prior to the
initiation of this study.
Also shown in Table 1, 93.2% (n = 110) of all
patients presented with at least one
comorbidity, the most common being
hypertension (n = 74, 62.7%), hyperlipidemia
(n = 53, 44.9%), and diabetes (n = 36, 30.5%).
The leg was the most common infection site
(n = 48, 40.7%), followed by the foot (n = 20,
16.9%) and arm (n = 15, 12.7%). Most patients
were afebrile, with only 3.4% (n = 2) of
oritavancin and 1.7% (n = 1) of SoC patients
presenting with fever (C100.4 F).
Baseline microbiology data (Table 2) were
available for 23.7% (n = 14) of oritavancin and
20.3% (n = 12) of SoC patients. All patients with
microbiology data presented with at least one
gram-positive pathogen. Four patients (2
oritavancin and 2 SoC) had a mix of
gram-positive and -negative pathogens.
Staphylococcus aureus was the most common
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Table 1 Patient demographics and baseline characteristics
Oritavancin (N5 59) SoC (N5 59) Total (N5 118) P value
Age (years)
Mean (SD) 65.3 (16.7) 63.8 (16.5) 64.6 (16.5)
Median (min, max) 68 (23, 94) 68 (18, 90) 68 (18, 94) 0.572
C65 years, n (%) 34 (57.6%) 34 (57.6%) 68 (57.6%) 1.000
Male, n (%) 29 (49.2%) 21 (35.6%) 50 (42.4%) 0.136
Race, n (%) 0.878
White 55 (93.2%) 53 (89.8%) 108 (91.5%)
Black 3 (5.1%) 3 (5.1%) 6 (5.1%)
Asian 0 (0.0%) 1 (1.7%) 1 (0.8%)
Unknown 1 (1.7%) 2 (3.4%) 3 (2.5%)
Weight (kg)
Mean (SD) 84.4 (27.0) 88.6 (31.9) 86.5 (29.5)
Median (min, max) 81.6 (45, 205) 79.8 (39, 188) 80.3 (39, 205) 0.698
Height (cm)
Mean (SD) 170.3 (9.2) 170.4 (11.4) 170.3 (10.3)
Median (min, max) 170.2 (152, 188) 167.6 (150, 196) 170.2 (150, 196) 0.802
BMI (kg/m2)
Mean (SD) 28.9 (8.6) 30.2 (9.4) 29.6 (9.0)
Median (min, max) 28.0 (17.2, 72.9) 27.1 (16.6, 61.3) 27.6 (16.6, 72.9) 0.714
C30 kg/m2, n (%) 19 (32.2%) 22 (37.3%) 41 (34.7%) 0.562
Insurance status, n (%) 0.352
Medicare 37 (62.7%) 31 (52.5%) 68 (57.6%)
Medicaid 0 (0.0%) 1 (1.7%) 1 (0.8%)
Commercial 22 (37.3%) 27 (35.8%) 49 (41.5%)
Patient referral location, n (%) 0.478
ER 4 (6.8%) 1 (1.7%) 5 (4.2%)
Hospital, observational unit 1 (1.7%) 0 (0.0%) 1 (0.8%)
Hospital, inpatient 13 (22.0%) 15 (25.4%) 28 (23.7%)
Physician’s ofﬁce 41 (69.5%) 41 (69.5%) 82 (69.5%)
LTCF/SNF 0 (0.0%) 1 (1.7%) 1 (0.8%)
Unknown 0 (0.0%) 1 (1.7%) 1 (0.8%)
Patients with any comorbidity, n (%) 53 (89.8%) 57 (96.6%) 110 (93.2%) 0.272
Most common comorbidities, n (%)
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causative pathogen identified in both groups
(14/14 in oritavancin and 9/12 in SoC). In S.
aureus isolates, MRSA was found in 78.6% of
oritavancin patients and 77.8% of SoC patients,
consistent with recent MRSA epidemiological
findings [12].
Clinical Effectiveness Results
Clinical effectiveness was assessed at a
prescheduled follow-up visit, which took place
5–30 days after completion of index treatment.
Table 1 continued
Oritavancin (N5 59) SoC (N5 59) Total (N5 118) P value
Diabetes 18 (30.5%) 18 (30.5%) 36 (30.5%) 1.000
Chronic obstructive pulmonary disease 8 (13.6%) 5 (8.5%) 13 (11.0%) 0.378
Hypertension 35 (59.3%) 39 (66.1%) 74 (62.7%) 0.446
Hyperlipidemia 25 (42.4%) 28 (47.5%) 53 (44.9%) 0.579
Depression 10 (16.9%) 12 (20.3%) 22 (18.6%) 0.636
Coronary artery disease 14 (23.7%) 16 (27.1%) 30 (25.4%) 0.672
Renal disease 11 (18.6%) 8 (13.6%) 19 (16.1%) 0.452
Disease state/condition, n (%) 1.000
Cellulitis/erysipelas 34 (57.6%) 34 (57.6%) 68 (57.6%)
Major cutaneous abscess 14 (23.7%) 14 (23.7%) 28 (23.7%)
Wound infection 11 (18.6%) 11 (18.6%) 22 (18.6%)
Traumatic 6 (10.2%) 3 (5.1%) 9 (7.6%)
Surgical 5 (8.5%) 8 (13.6%) 13 (11.0%)
Baseline temperature C100.4 F, n (%) 2 (3.4%) 1 (1.7%) 3 (2.5%)
Body part/location of infection, n (%)
Face 2 (3.4%) 3 (5.1%) 5 (4.2%)
Neck 0 (0.0%) 1 (1.7%) 1 (0.8%)
Chest 1 (1.7%) 1 (1.7%) 2 (1.7%)
Trunk 6 (10.2%) 7 (11.9%) 13 (11.0%)
Back 0 (0.0%) 3 (5.1%) 3 (2.5%)
Arm 10 (16.9%) 5 (8.5%) 15 (12.7%)
Hand 6 (10.2%) 6 (10.2%) 12 (10.2%)
Buttock 3 (5.1%) 4 (6.8%) 7 (5.9%)
Leg 27 (45.8%) 21 (35.6%) 48 (40.7%)
Foot 10 (16.9%) 10 (16.9%) 20 (16.9%)
Groin 1 (1.7%) 0 (0.0%) 1 (0.8%)
BMI body mass index, ER emergency room, LTCF long-term care facility, SD standard deviation, SNF skilled nursing
facility, SoC standard of care
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Mean days to follow-up was 16.7 for oritavancin
and 17.6 for SoC. Similar clinical effectiveness
of success rate at 5–30 days post-treatment was
observed between oritavancin and SoC
antibiotics (90.2% vs. 77.4%, 95% CI of
difference: -4.5%, 30.1%, P = 0.134) and
across all subgroups (Fig. 1). The clinical cure
rate was statistically higher in oritavancin
patients (73.2%) vs. SoC patients (48.4%;
P = 0.0315). Within the SoC group, rates of
success and cure for specific IV antibiotics were:
daptomycin 68.8% success and 50.0% cure;
dalbavancin 75.0% success and 37.5% cure;
vancomycin 100.0% success and 33.3% cure.
Sensitivity Analysis of Clinical
Effectiveness Results
Sensitivity analyses of clinical effectiveness
responses (cured, improved, failure, or
non-evaluable) found that results remained
similar regardless of how non-evaluable
patients were accounted. When non-evaluable
patients were categorized as treatment failures,
the clinical success percentage remained higher
in the oritavancin than SoC cohort
(oritavancin, 62.7%; SoC, 40.7%; P = 0.0166).
Likewise, when non-evaluable patients were
treated as successes, the percentage of patients
with clinical success was similar across both
cohorts (oritavancin, 93.2%; SoC, 88.1%;
P = 0.3422).
Economic Results
Mean total costs were lower for oritavancin
compared with SoC antibiotics ($4035 vs. $6354,
P = 0.0107), representing $2319 per patient
savings with oritavancin (Fig. 2). This cost
differential was driven by both lower medication
costs for oritavancin compared with SoC
antibiotics ($3260 vs. $5157, P = 0.0038) and
reduced non-medication related costs ($830 vs.
$1198, P\0.0001), such as infusion supplies ($19
vs. $84), infusion administration personnel ($149
vs. $722), and outpatient/office costs ($203 vs.
$276). Costs during the index treatment period
alone were also lower for oritavancin compared
with SoC antibiotics ($3114 vs.. $5144,
P = 0.0009). Costs during the 30-day post index
treatment period were comparable for both
cohorts ($921 vs. $1210, NS).
Mean total costs for oritavancin patients
during the study period were predictable and
consistent across all clinical subgroups (Fig. 3),
ranging from $3600 to $4200. Total costs for
SoC subgroups varied substantially, from $4400
to $9700. Savings with oritavancin were
Table 2 Baseline infection-site culture
Oritavancin (N5 59) SoC (N5 59) Total (N5 118)
Patients with microbiology results, n (%) 14 (23.7%) 12 (20.3%) 26 (22.0%)
Gram-positive organisms only 12 (20.3%) 10 (16.9%) 22 (18.6%)
Both gram-positive and -negative organisms 2 (3.4%) 2 (3.4%) 4 (3.4%)
Gram-negative organisms only 0 (0.0%) 0 (0.0%) 0 (0.0%)
Patients with gram-positive organisms, n 14 12 26
Staphylococcus aureus, n 14 9 23
MRSA, n 11 7 18
MSSA, n 3 2 5
Staphylococcus lugdunensis, n 0 2 2
Enerococcus faecalis, n 2 3 5
MRSA methicillin-resistant Staphylococcus aureus, MSSA methicillin-sensitive Staphylococcus aureus, SoC standard of care
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observed across all clinical subgroups, with
patients diagnosed with wound infection
demonstrating the greatest savings, at $5775.
Healthcare Resource Utilization
Oritavancin patients required 1 day of therapy
compared to a mean of 7.2 days of therapy for
SoC patients. Approximately one-quarter of
oritavancin patients (n = 16, 27.1%) required
additional post-treatment oral or IV antibiotics,
but almost double this proportion of SoC
patients (n = 31, 52.5%) required additional
antibiotics (Table 3).
In total, 26 patients had a hospital admission
within 30 days prior to index treatment (11
oritavancin, 15 SoC). One SoC patient
experienced an ER visit during the index
treatment period for complications related to
Fig. 1 Clinical response evaluation at 5–30 days post-treatment by subgroup
Fig. 2 Mean costs from initiation of study drug to end of study period
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the peripherally inserted central catheter line.
No oritavancin patients visited an ER during the
index period. For the post-index treatment
period, two patients in the SoC cohort had an
ER visit and three patients in the SoC cohort
were hospitalized. No patients in the
oritavancin cohort were hospitalized or
required an ER visit following index treatment
(Table 3).
DISCUSSION
In the current healthcare environment, there is
substantial pressure to reduce costs and resource
use while maintaining or improving quality of
care. This study analyzed the effectiveness of
ABSSSI treatment in an outpatient infusion
center with single-dose oritavancin compared
to SoC antibiotics and found that oritavancin
was clinically comparable to SoC antibiotics,
but less costly and resource intensive.
For overall effectiveness (cured or improved),
oritavancin showed similar rates (90.2% cured
or improved) to SoC antibiotics (77.4%).
Notably, the clinical cure rate was statistically
higher for the oritavancin cohort (73.2 vs.
48.4%; P = 0.0315). The effectiveness rates in
this real-world study were comparable to rates
seen in clinical trials. The phase 3 SOLO1 trial
compared single-dose oritavancin to 7–10 days
of twice daily vancomycin. Oritavancin
demonstrated comparable effectiveness for the
primary composite endpoint (cessation of
spreading or reduction in lesion size) at early
clinical evaluation (ECE) at 48–72 h (82.3% for
oritavancin, 78.9% for vancomycin, 95% CI
-1.6, 8.4); investigator-assessed clinical cure at
Fig. 3 Mean costs by patient subgroups
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post-therapy evaluation (79.6% for oritavancin,
80.0% for vancomycin, 95% CI -5.5, 4.7); and
lesion size reduction C20% at ECE (86.9% for
oritavancin, 82.9% for vancomycin, 95% CI
-0.5, 8.6). [13] Similar results were seen in the
phase 3 SOLO2 trial of single-dose oritavancin
compared to twice daily vancomycin for
7–10 days. Oritavancin demonstrated
comparable effectiveness for the primary
composite endpoint at ECE (80.1 vs. 82.9%),
investigator-assessed clinical cure at
post-treatment evaluation (82.7 vs. 80.5%),
and C20% lesion size reduction at ECE (85.9
vs. 85.3%). Clinical response rates were similar
across sub-groups, including BMI, age, MRSA,
gender, and race [13].
This analysis also found that oritavancin
demonstrated consistent clinical effectiveness
across subgroup populations with various
clinical characteristics, including MRSA. This
consistency is supported by a recent analysis of
pooled SOLO study results that used a modified
Eron severity classification system for skin and
soft tissue infections to evaluate oritavancin
compared with vancomycin in patients with
varying degrees of morbidity and disease
severity. The study concluded that single-dose
oritavancin was an effective alternative to
multi-dose IV vancomycin for the treatment of
ABSSSI patients within modified Eron Classes
I–III and that management in the inpatient or
outpatient setting had comparable efficacy [14].
Based on these study results, the clinical
effectiveness of oritavancin and SoC IV
antibiotics in the real-world outpatient setting
is comparable to that seen in clinical trials. This
study further found that while outcomes are
comparable, outpatient treatment with
Table 3 Healthcare resource utilization
Oritavancin
(N5 59), n (%)
SoC
(N5 59), n (%)
Total
(N5 118), n (%)
Patient visited ER
Prior to index treatment 12 (20.3%) 9 (15.6%) 21 (17.8%)
During index treatment 0 (0.0%) 1 (1.7%) 1 (0.8%)
Post index treatment 0 (0.0%) 2 (3.4%) 2 (1.7%)
Patient hospitalized
Prior to index treatment 11 (18.6) 15 (25.4%) 26 (22.0%)
During index treatment 0 (0.0%) 0 (0.0%) 0 (0.0%)
Post-index treatment 0 (0.0%) 3 (5.1%) 3 (2.5%)
Index ABX
Oritavancin 59 (100%) 0 (0%) 59 (50.0%)
Vancomycin 0 (0%) 3 (5.1%) 3 (2.5%)
Dalbavancin 0 (0%) 15 (25.4%) 15 (12.7%)
Daptomycin 0 (0%) 34 (57.6%) 34 (28.8%)
Other IV ABX 0 (0%) 7 (11.9%) 7 (5.9%)
Patient received any non-study ABX post-index ABX, n (%) 16 (27.1%) 31 (52.5%) 47(39.8%)
Received IV/IM ABX w or w/o oral 9 (15.3%) 18 (30.5%) 27(22.9%)
Received oral ABX only 7 (11.9%) 13 (22.0%) 20 (16.9%)
ABX antibiotics, ER emergency room, IM intramuscular, IV intravenous, SoC standard of care
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oritavancin was less expensive and less resource
intensive than outpatient treatment with SoC
IV antibiotics, with a mean cost savings of
$2319 per patient. Cost savings were derived
from both lower medication costs and fewer
healthcare resources needed to deliver
treatment. Importantly, this study also found
that the cost of outpatient treatment with
oritavancin was substantially lower than
reported costs for inpatient management of
ABSSSI. Ektare et al. estimated total costs to
the payer of $9813 to $18,014 for inpatient
treatment of ABSSSI [5]. A 2015 analysis by
Lodise et al. based on a retrospective analysis of
hospital discharge data from the Premier
Research Database found that hospital costs
for inpatient care ranged from $5851 to $12,457
for patients without life-threatening infections
[3]. The Lodise analysis also determined that
94% of all hospitalized ABSSSI patients did not
have a life-threatening infection, indicating
that up to 535,100 hospital admissions in the
US could be avoided with greater use of the
outpatient setting [2, 3]. Further, in this study
the majority of patients had no prior
hospitalization (81.3% of oritavancin and
74.6% of SoC), and there was a low rate of ER
visits and hospitalization following outpatient
treatment (0% oritavancin vs. 3.4% SoC, NS; 0%
oritavancin vs. 5.1% SoC, NS). This indicates
that effective treatment can be provided
entirely in the outpatient setting for most
patients.
These findings and other recent
investigations [8–11] provide a clear
implication of the potential for cost savings in
moving ABSSSI treatment from the inpatient to
outpatient setting. When this is coupled with
the cost savings obtained from using single-dose
over SoC antibiotics, outpatient treatment of
ABSSSI with oritavancin may provide
much-needed cost savings. These cost savings
accrue not only to the health care system, but
also to patients, as many patients are
responsible for a co-insurance of *20% on the
cost of outpatient services. Further, oritavancin
patients visited the infusion center only once
for drug administration, compared to a mean of
7 visits for SoC patients. Given no difference in
clinical outcomes, both the cost to the patient
and overall treatment burden on patients
should be considered when making
appropriate treatment decisions.
Strengths/Limitations
A key strength of this analysis is that it includes
both clinical outcomes and the economic
impact of treatment with oritavancin in an
outpatient center. Additionally, the results seen
in the sensitivity analysis demonstrate the
robustness of the primary effectiveness
outcome, and sub-group analysis found that
the results are consistent across multiple patient
subgroups. Further, results are comparable to
those seen in the two prior phase 3 clinical trials
of oritavancin.
While this is the first study to look at
oritavancin treatment for ABSSSI in an
outpatient setting, several limitations should
be considered when interpreting this study’s
findings. First, this was a retrospective,
observational study performed at a single site.
As such, it is subject to limitations such as lack
of external validity, small sample size, and
possible practice pattern differences such as
type of SoC drugs used. Furthermore, while
this study population is representative of ABSSSI
patients typically treated at an outpatient
infusion center site, it may not represent
ABSSSI patients in other settings (such as
hospitals, ER, hospital-based outpatient
parenteral antibiotic therapy, or other
outpatient centers). Further research is needed
in other settings of care and with a larger
sample size to validate the findings in this
early study.
While this retrospective study captures
real-world assessment and treatment choices,
it is not known if this practice’s choices are
consistent with other institutions. Dalbavancin
was used in 25% of the SoC group; however,
Premier Hospital data show that national usage
is less than 1% of ABSSSI treatments in 2015
[15]. Notably, in this study only 20% of patients
had lesion size recorded in the medical chart.
While lesion size measurement is part of the US
Food and Drug Administration definition of
ABSSSI, it is not known how frequently lesion
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size is actually measured and recorded in the
real world, although these study results indicate
it is not an important criterion in treatment
decision-making [16]. Additionally, while more
than one-half of patients in this study had a
follow-up visit that occurred within the
assigned 5–30-day period, 30.5% of
oritavancin and 47.5% of SoC patients did not
have documented follow-up within this time
frame; 2 patients had no outcomes data
recorded; 5 patients had follow-up visits
within the first 5 days; 13 patients had
follow-up after the pre-specified 30-day
window; 26 patients did not return to the
infusion center for follow-up. This likely
reflects the location of this infusion center in a
popular vacation destination and with a large
catchment area that reaches into the
neighboring state, making it difficult for many
patients to return for follow-up. Last,
microbiology data were available for only 22%
of patients, which may reflect the real-world
practice of making treatment decisions without
information on ABSSSI pathogen type.
CONCLUSION
This study, conducted in an outpatient infusion
center, demonstrates that real-world treatment
of ABSSSI with single-dose oritavancin provides
equivalent outcomes compared with SoC
antibiotics with 6 fewer days of treatment and
a cost savings of greater than $2000. It also
provides evidence of lower costs relative to
hospital inpatient care, an important
consideration when hospital costs comprise
one-third of total healthcare spending. In an
era of continued pressure to reduce costs
without compromising outcomes, outpatient
treatment with single-dose oritavancin may
present a solution to the management of
ABSSSI patients.
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